* evidence of moderate covid-19 per fda severity categorization * pregnant or lactating and breast feeding or planning on either during the study * has a documented infection other than covid-19 * has received a covid-19 vaccine * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit

* evidence of moderate covid-19 per fda severity categorization * pregnant or lactating and breast feeding or planning on either during the study * has a documented infection other than covid-19 * has received a covid-19 vaccine * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit

- evidence of moderate covid-19 per fda severity categorization - pregnant or lactating and breast feeding or planning on either during the study - has a documented infection other than covid-19 - has received a covid-19 vaccine - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit

- evidence of moderate covid-19 per fda severity categorization - pregnant or lactating and breast feeding or planning on either during the study - has a documented infection other than covid-19 - has received a covid-19 vaccine - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit